{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T16:17:12Z","timestamp":1788797832127,"version":"build-2803163510"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"7-8","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"A. Menarini Pharma GmbH"},{"DOI":"10.13039\/501100005788","name":"Medical University of Vienna","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005788","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Wien Klin Wochenschr"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1007\/s00508-019-1481-x","type":"journal-article","created":{"date-parts":[[2019,4,8]],"date-time":"2019-04-08T07:02:56Z","timestamp":1554706976000},"page":"165-173","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Ranolazine: impact on quality of life in patients with stable angina pectoris, results from an observational study in Austria \u2013 the ARETHA\u00a0AT study"],"prefix":"10.1007","volume":"131","author":[{"given":"Robert","family":"Zweiker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josef","family":"Aichinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Metzler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Wallner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9382-5113","authenticated-orcid":false,"given":"Georg","family":"Delle-Karth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,4,8]]},"reference":[{"key":"1481_CR1","doi-asserted-by":"publisher","first-page":"611","DOI":"10.2215\/CJN.03871106","volume":"2","author":"PA McCullough","year":"2007","unstructured":"McCullough PA. Coronary artery disease. Clin J Am Soc Nephrol. 2007;2:611\u20136. \n                    https:\/\/doi.org\/10.2215\/CJN.03871106\n                    \n                  .","journal-title":"Clin J Am Soc Nephrol"},{"key":"1481_CR2","volume-title":"Ranexa: summary of product characteristics","author":"EMA","year":"2013","unstructured":"EMA. Ranexa: summary of product characteristics. London: European Medicines Agency; 2013."},{"key":"1481_CR3","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1161\/CIRCULATIONAHA.107.724880","volume":"116","author":"BM Scirica","year":"2007","unstructured":"Scirica BM, Morrow DA, Hod H, Murphy SA, Belardinelli L, Hedgepeth CM, et al. Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the Metabolic Efficiency With Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial. Circulation. 2007;116:1647\u201352. \n                    https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.107.724880\n                    \n                  .","journal-title":"Circulation"},{"issue":"34","key":"1481_CR4","doi-asserted-by":"publisher","first-page":"2949","DOI":"10.1093\/eurheartj\/eht296","volume":"2013","author":"G Montalescot","year":"2013","unstructured":"Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, Budaj A, et\u00a0al. ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart\u00a0J. 2013;2013(34):2949\u20133003. \n                    https:\/\/doi.org\/10.1093\/eurheartj\/eht296\n                    \n                  .","journal-title":"Eur Heart J"},{"key":"1481_CR5","volume-title":"Amtliche Verlautbarung der \u00f6sterreichischen Sozialversicherung: 71. \u00c4nderung des Erstattungskodex","author":"Federation of Austrian Social Insurance Institutions","year":"2010","unstructured":"Federation of Austrian Social Insurance Institutions. Amtliche Verlautbarung der \u00f6sterreichischen Sozialversicherung: 71. \u00c4nderung des Erstattungskodex. Vienna: Hauptverband der \u00f6sterreichischen Sozialversicherungstr\u00e4ger; 2010."},{"key":"1481_CR6","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1007\/s00508-017-1248-1","volume":"129","author":"IM Lang","year":"2017","unstructured":"Lang IM, Badr-Eslam R, Greenlaw N, Young R, Steg PG. Management and clinical outcome of stable coronary artery disease in Austria: results from 5 years of the CLARIFY registry. Wien Klin Wochenschr. 2017;129:879\u201392. \n                    https:\/\/doi.org\/10.1007\/s00508-017-1248-1\n                    \n                  .","journal-title":"Wien Klin Wochenschr"},{"key":"1481_CR7","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1111\/j.1365-2929.2005.02237.x","volume":"39","author":"G Pell","year":"2005","unstructured":"Pell G. Use and misuse of Likert scales. Med Educ. 2005;39:970. \n                    https:\/\/doi.org\/10.1111\/j.1365-2929.2005.02237.x\n                    \n                  . author reply 971.","journal-title":"Med Educ"},{"key":"1481_CR8","first-page":"4","volume":"13","author":"M Pichler","year":"2006","unstructured":"Pichler M. Symptomatische stabile Angina pectoris: Epidemiologie, therapeutische Option und innovative Therapieans\u00e4tze. J\u00a0Kardiol. 2006;13:4\u20135.","journal-title":"J Kardiol"},{"key":"1481_CR9","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.ijcard.2015.10.180","volume":"205","author":"D Alexopoulos","year":"2016","unstructured":"Alexopoulos D, Kochiadakis G, Afthonidis D, Barbetseas J, Kelembekoglou P, Limberi S, et al. Ranolazine reduces angina frequency and severity and improves quality of life: observational study in patients with chronic angina under ranolazine treatment in Greece (OSCAR-GR). Int J Cardiol. 2016;205:111\u20136. \n                    https:\/\/doi.org\/10.1016\/j.ijcard.2015.10.180\n                    \n                  .","journal-title":"Int J Cardiol"},{"key":"1481_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4172\/2155-9880.1000412","volume":"6","author":"H Diedrichs","year":"2015","unstructured":"Diedrichs H, Wollenberg U, Schmerbach K, Limberg R, Schiffhorst G, Zeiher AM. Application of ranozaline in stable angina pectoris therapy (ARETHA):\u00a0real-world data from an observational study. J\u00a0Clin Exp Cardiolog. 2015;6:1\u20136.","journal-title":"J Clin Exp Cardiolog"},{"key":"1481_CR11","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1001\/jama.291.3.309","volume":"291","author":"BR Chaitman","year":"2004","unstructured":"Chaitman BR, Pepine CJ, Parker JO, Skopal J, Chumakova G, Kuch J, et\u00a0al. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a\u00a0randomized controlled trial. JAMA. 2004;291:309\u201316. \n                    https:\/\/doi.org\/10.1001\/jama.291.3.309\n                    \n                  .","journal-title":"JAMA"},{"key":"1481_CR12","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1016\/j.jacc.2013.02.011","volume":"61","author":"M Kosiborod","year":"2013","unstructured":"Kosiborod M, Arnold SV, Spertus JA, McGuire DK, Li Y, Yue P, et\u00a0al. Evaluation of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina: results from the TERISA randomized clinical trial (type 2 diabetes evaluation of ranolazine in subjects with chronic stable angina). J\u00a0Am Coll Cardiol. 2013;61:2038\u201345. \n                    https:\/\/doi.org\/10.1016\/j.jacc.2013.02.011\n                    \n                  .","journal-title":"J Am Coll Cardiol"},{"key":"1481_CR13","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1016\/j.ijcard.2015.11.060","volume":"203","author":"YM Lopatin","year":"2016","unstructured":"Lopatin YM, Rosano GMC, Fragasso G, Lopaschuk GD, Seferovic PM, Gowdak LHW, et\u00a0al. Rationale and benefits of trimetazidine by acting on cardiac metabolism in heart failure. Int J Cardiol. 2016;203:909\u201315. \n                    https:\/\/doi.org\/10.1016\/j.ijcard.2015.11.060\n                    \n                  .","journal-title":"Int J Cardiol"},{"key":"1481_CR14","doi-asserted-by":"publisher","first-page":"D19","DOI":"10.1093\/eurheartj\/sup014","volume":"11","author":"R Ferrari","year":"2009","unstructured":"Ferrari R. A step further with ivabradine: SIGNIFY (Study assessInG the morbidity\u2013mortality beNefits of the If inhibitor ivabradine in patients with coronarY artery disease). Eur Heart\u00a0J. 2009;11:D19\u2013D27.","journal-title":"Eur Heart J"},{"key":"1481_CR15","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1016\/S0140-6736(02)08265-X","volume":"359","author":"IONA Study Group","year":"2002","unstructured":"IONA Study Group. Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil In Angina (IONA) randomised trial. Lancet. 2002;359:1269\u201375. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(02)08265-X\n                    \n                  .","journal-title":"Lancet"},{"key":"1481_CR16","volume-title":"Nicht-interventionelle Studie \u201eARETHA\u201c: Anwendung von Ranolazin in der Therapie der stabilen Angina pectoris","author":"H Schmutzler","year":"2014","unstructured":"Schmutzler H. Nicht-interventionelle Studie \u201eARETHA\u201c: Anwendung von Ranolazin in der Therapie der stabilen Angina pectoris. Berlin: Berlin-Chemie AG; 2014."},{"key":"1481_CR17","first-page":"26","volume":"40","author":"A.T.I. Arzneimittelinformation Berlin","year":"2009","unstructured":"A.T.I. Arzneimittelinformation Berlin. Ranolazin (Ranexa) bei chronisch stabila Angina Pectoris. Arznei Telegr. 2009;40:26\u20137.","journal-title":"Arznei Telegr"},{"key":"1481_CR18","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1023\/A:1007744109064","volume":"13","author":"H Szwed","year":"1999","unstructured":"Szwed H, Sadowski Z, Pachocki R, Domza\u0142-Boche\u0144ska M, Szymczak K, Szyd\u0142owski Z, et al. The antiischemic effects and tolerability of trimetazidine in coronary diabetic patients. A substudy from TRIMPOL-1. Cardiovasc Drugs Ther. 1999;13:217\u201322.","journal-title":"Cardiovasc Drugs Ther"},{"key":"1481_CR19","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/S0140-6736(08)61170-8","volume":"372","author":"K Fox","year":"2008","unstructured":"Fox K, Ford I, Steg PG, Tendera M, Ferrari R. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a\u00a0randomised, double-blind, placebo-controlled trial. Lancet. 2008;372:807\u201316. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(08)61170-8\n                    \n                  .","journal-title":"Lancet"},{"key":"1481_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.amjcard.2009.02.059","volume":"104","author":"WE Boden","year":"2009","unstructured":"Boden WE, O\u2019Rourke RA, Teo KK, Maron DJ, Hartigan PM, Sedlis SP, et al. Impact of optimal medical therapy with or without percutaneous coronary intervention on long-term cardiovascular end points in patients with stable coronary artery disease (from the COURAGE Trial). Am J Cardiol. 2009;104:1\u20134. \n                    https:\/\/doi.org\/10.1016\/j.amjcard.2009.02.059\n                    \n                  .","journal-title":"Am J Cardiol"},{"key":"1481_CR21","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(17)32714-9.","volume":"391","author":"R Al-Lamee","year":"2018","unstructured":"Al-Lamee R, Thompson D, Dehbi H\u2011M, Sen S, Tang K, Davies J, et al. Percutaneous coronary intervention in stable angina (ORBITA): a\u00a0double-blind, randomised controlled trial. Lancet. 2018;391:31\u201340. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(17)32714-9\n                    \n                  .","journal-title":"Lancet"},{"key":"1481_CR22","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1161\/CIRCULATIONAHA.115.019768","volume":"133","author":"KP Alexander","year":"2016","unstructured":"Alexander KP, Weisz G, Prather K, James S, Mark DB, Anstrom KJ, et al. Effects of ranolazine on angina and quality of life after percutaneous coronary intervention with incomplete revascularization: results from the ranolazine for incomplete vessel revascularization (RIVER-PCI) trial. Circulation. 2016;133:39\u201347. \n                    https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.115.019768\n                    \n                  .","journal-title":"Circulation"},{"key":"1481_CR23","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/S0140-6736(15)00459-6.","volume":"387","author":"G Weisz","year":"2016","unstructured":"Weisz G, G\u00e9n\u00e9reux P, I\u00f1iguez A, Zurakowski A, Shechter M, Alexander KP, et al. Ranolazine in patients with incomplete revascularisation after percutaneous coronary intervention (RIVER-PCI): a\u00a0multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2016;387:136\u201345. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(15)00459-6\n                    \n                  .","journal-title":"Lancet"},{"key":"1481_CR24","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1177\/2047487316648475","volume":"23","author":"G Ambrosio","year":"2016","unstructured":"Ambrosio G, Komajda M, Mugelli A, Lopez-Sendon J, Tamargo J, Camm J. Management of stable angina: a commentary on the European Society of Cardiology guidelines. Eur J Prev Cardiol. 2016;23:1401\u201312. \n                    https:\/\/doi.org\/10.1177\/2047487316648475\n                    \n                  .","journal-title":"Eur J Prev Cardiol"},{"key":"1481_CR25","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.jcmg.2011.03.007","volume":"4","author":"PK Mehta","year":"2011","unstructured":"Mehta PK, Goykhman P, Thomson LEJ, Shufelt C, Wei J, Yang Y, et\u00a0al. Ranolazine improves angina in women with evidence of myocardial ischemia but no obstructive coronary artery disease. Jacc Cardiovasc Imaging. 2011;4:514\u201322. \n                    https:\/\/doi.org\/10.1016\/j.jcmg.2011.03.007\n                    \n                  .","journal-title":"Jacc Cardiovasc Imaging"},{"key":"1481_CR26","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1161\/CIRCULATIONAHA.116.023266","volume":"135","author":"VR Taqueti","year":"2017","unstructured":"Taqueti VR, Shaw LJ, Cook NR, Murthy VL, Shah NR, Foster CR, et\u00a0al. Excess cardiovascular risk in women relative to men referred for coronary angiography is associated with severely impaired coronary flow reserve, not obstructive disease. Circulation. 2017;135:566\u201377. \n                    https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.116.023266\n                    \n                  .","journal-title":"Circulation"},{"key":"1481_CR27","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/j.amjcard.2011.04.017","volume":"108","author":"RH Miles","year":"2011","unstructured":"Miles RH, Passman R, Murdock DK. Comparison of effectiveness and safety of ranolazine versus amiodarone for preventing atrial fibrillation after coronary artery bypass grafting. Am J Cardiol. 2011;108:673\u20136. \n                    https:\/\/doi.org\/10.1016\/j.amjcard.2011.04.017\n                    \n                  .","journal-title":"Am J Cardiol"},{"key":"1481_CR28","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1093\/eurheartj\/ehi586","volume":"26","author":"J-C Tardif","year":"2005","unstructured":"Tardif J\u2011C, Ford I, Tendera M, Bourassa MG, Fox K. Efficacy of ivabradine, a\u00a0new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart\u00a0J. 2005;26:2529\u201336. \n                    https:\/\/doi.org\/10.1093\/eurheartj\/ehi586\n                    \n                  .","journal-title":"Eur Heart J"},{"key":"1481_CR29","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1161\/CIRCULATIONAHA.107.763912","volume":"119","author":"DA Morrow","year":"2009","unstructured":"Morrow DA, Scirica BM, Chaitman BR, McGuire DK, Murphy SA, Karwatowska-Prokopczuk E, et al. Evaluation of the glycometabolic effects of ranolazine in patients with and without diabetes mellitus in the MERLIN-TIMI 36 randomized controlled trial. Circulation. 2009;119:2032\u20139. \n                    https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.107.763912\n                    \n                  .","journal-title":"Circulation"},{"key":"1481_CR30","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.pharmthera.2011.11.003","volume":"133","author":"S Sossalla","year":"2012","unstructured":"Sossalla S, Maier LS. Role of ranolazine in angina, heart failure, arrhythmias, and diabetes. Pharmacol Ther. 2012;133:311\u201323. \n                    https:\/\/doi.org\/10.1016\/j.pharmthera.2011.11.003\n                    \n                  .","journal-title":"Pharmacol Ther"},{"key":"1481_CR31","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1093\/eurheartj\/ehi495","volume":"27","author":"AD Timmis","year":"2006","unstructured":"Timmis AD, Chaitman BR, Crager M. Effects of ranolazine on exercise tolerance and HbA1c in patients with chronic angina and diabetes. Eur Heart\u00a0J. 2006;27:42\u20138. \n                    https:\/\/doi.org\/10.1093\/eurheartj\/ehi495\n                    \n                  .","journal-title":"Eur Heart J"},{"key":"1481_CR32","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1086\/682427","volume":"5","author":"SS Khan","year":"2015","unstructured":"Khan SS, Cuttica MJ, Beussink-Nelson L, Kozyleva A, Sanchez C, Mkrdichian H, et al. Effects of ranolazine on exercise capacity, right ventricular indices, and hemodynamic characteristics in pulmonary arterial hypertension: a\u00a0pilot study. Pulm Circ. 2015;5:547\u201356. \n                    https:\/\/doi.org\/10.1086\/682427\n                    \n                  .","journal-title":"Pulm Circ"},{"key":"1481_CR33","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.jchf.2012.12.002","volume":"1","author":"LS Maier","year":"2013","unstructured":"Maier LS, Layug B, Karwatowska-Prokopczuk E, Belardinelli L, Lee S, Sander J, et al. RAnoLazIne for the treatment of diastolic heart failure in patients with preserved ejection fraction: the RALI-DHF proof-of-concept study. Jacc Heart Fail. 2013;1:115\u201322. \n                    https:\/\/doi.org\/10.1016\/j.jchf.2012.12.002\n                    \n                  .","journal-title":"Jacc Heart Fail"},{"key":"1481_CR34","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.ijcard.2016.06.150","volume":"220","author":"AJ Manolis","year":"2016","unstructured":"Manolis AJ, Poulimenos LE, Ambrosio G, Kallistratos MS, Lopez-Sendon J, Dechend R, et al. Medical treatment of stable angina: a tailored therapeutic approach. Int J Cardiol. 2016;220:445\u201353. \n                    https:\/\/doi.org\/10.1016\/j.ijcard.2016.06.150\n                    \n                  .","journal-title":"Int J Cardiol"}],"container-title":["Wiener klinische Wochenschrift"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-019-1481-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00508-019-1481-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-019-1481-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,6]],"date-time":"2020-04-06T23:27:13Z","timestamp":1586215633000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00508-019-1481-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":34,"journal-issue":{"issue":"7-8","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["1481"],"URL":"https:\/\/doi.org\/10.1007\/s00508-019-1481-x","relation":{},"ISSN":["0043-5325","1613-7671"],"issn-type":[{"value":"0043-5325","type":"print"},{"value":"1613-7671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"18 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"R.\u00a0Zweiker has relationships with following drug companies: Novartis, Servier, AstraZeneca, DaiichiSankyo, Amgen, Merck, Gebro, Sanofi, Boehringer, Abbott, Bayer and Menarini. These relationships include research grants, membership of scientific advisory boards, lecture activities and congress invitations. I.\u00a0Lang has relationships with drug companies including AOPOrphan Pharmaceuticals, Actelion, Bayer-Schering, Astra-Zeneca, Menarini, Servier, Cordis, Medtronic, GSK, and Ferrer. In addition, to being investigator in trials involving these companies, I.\u00a0Lang\u2019s relationships include consultancy service, research grants, and membership of scientific advisory boards. I.\u00a0Lang had\u00a0access to all study data and analyses, was involved in interpretation of data; writing of the paper and decision to submit for publication. I.\u00a0Lang serves on the editorial board of the European Heart\u00a0Journal, Thrombosis and Haemostasis, and Pulmonary\u00a0Circulation. I.\u00a0Lang is not sitting on a\u00a0committee or\u00a0organization that may benefit from publication of this paper. E.\u00a0Wallner is employee of A.\u00a0Menarini Pharma GmbH Austria. G. Delle-Karth has relationships with following drug companies: Astra Zeneca, Amgen, Bayer, Boehringer Ingelheim, Daiichi-Sankyo MSD, Pfizer, Sanofi, and Menarini. These relationships include research grants, membership of scientific advisory boards, lecture activities and congress invitations. J.\u00a0Aichinger and B.\u00a0Metzler declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}